SEMA MISIR^1,*, SERAP OZER YAMAN², NINA PETROVIĆ^3,4, CEREN SUMER⁵, CEYLAN HEPOKUR¹, YUKSEL ALIYAZICIOGLU²

Oncology Research, Vol.30, No.4, pp. 157-172, 2022, DOI:10.32604/or.2022.027547 - 31 January 2023

Abstract Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for BC treatment. One of the significant challenges during the treatment of BC represents resistance to chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment. Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a large group of non-coding RNAs that covalently form closed circular loops by joining their 5′,… More >

UROS BUMBASIREVIC^1,2,*, MARKO ZIVKOVIC¹, MILOS PETROVIC¹, VESNA CORIC^2,3, NIKOLA LISICIC¹, NEBOJSA BOJANIC^1,2

Oncology Research, Vol.30, No.3, pp. 117-128, 2022, DOI:10.32604/or.2022.027511 - 12 January 2023

Abstract Seminomas are most commonly diagnosed in clinical stage I (CSI). After orchiectomy, approximately 15% of patients in this stage have subclinical metastases. Adjuvant radiotherapy (ART) delivered to the retroperitoneum and ipsilateral pelvic lymph nodes has been the mainstay of treatment for many years. Although highly efficient, with long-term cancer-specific survival (CSS) rates approaching almost 100%, ART is associated with considerable long-term consequences, particularly cardiovascular toxicity and increased risk of secondary malignancies (SMN). Therefore, active surveillance (AS) and adjuvant chemotherapy (ACT) were developed as alternative treatment options. While AS prevents patient overtreatment, it is associated with… More >

YUNG-SUNG YEH^1,2,3, HSIANG-LIN TSAI^4,5, YEN-CHENG CHEN^4,6, WEI-CHIH SU^4,6, PO-JUNG CHEN^4,6, TSUNG-KUN CHANG^4,6,7, CHING-CHUN LI⁴, CHING-WEN HUANG^4,5, JAW-YUAN WANG^{4,5,6,8,9,10,*}

Oncology Research, Vol.30, No.2, pp. 65-76, 2022, DOI:10.32604/or.2022.026659 - 05 January 2023

Abstract The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients with mCRC for metastasectomy remain undefined. This retrospective study compared the efficacy, safety, and survival of cycles of neoadjuvant chemotherapy/targeted therapy for such patients. Sixty-four patients with mCRC who received neoadjuvant chemotherapy/targeted therapy following metastasectomy were enrolled between January 2018 and April 2022. Twenty-eight patients received 6 cycles of chemotherapy/targeted therapy, whereas 36 patients received ≥7 cycles (median, 13; range, 7–20). Clinical outcomes, including response,… More >

Huihui Zhang, Jing Yan, Xiaoyong Ren, Ying Sheng, Zhenghui Wang, Jianmin Liang, Yan Yan, Yangyang Jia, Zhihui Li, Jin Hou^*

Oncologie, Vol.24, No.4, pp. 707-716, 2022, DOI:10.32604/oncologie.2022.027023 - 31 December 2022

Abstract Objective: To assess the efficacy and toxicity of nimotuzumab combined with neoadjuvant or induction chemotherapy for head and neck squamous cell carcinoma (HNSCC). Methods: Patients received intravenous nimotuzumab (400 mg, weekly for 1–3 weeks) combined with chemotherapy (5-fluorouracil/paclitaxel/docetaxel + nedaplatin/cisplatin for 1–2 cycles), prior to definitive surgical resection, radiotherapy or other treatments. The primary endpoint was the objective response rate (ORR). The secondary endpoints were tumor downstaging, complete response rate (CRR), partial response rate (PRR), disease control rate (DCR), R0 resection rate, pathological complete response (pCR), larynx preservation rate, overall survival (OS), progression-free survival (PFS), and… More >

Haojie Zhang¹, Xiaohong Wang^2,*, Yue Yu², Zhenlin Yang^3,*

Oncologie, Vol.24, No.2, pp. 247-259, 2022, DOI:10.32604/oncologie.2022.020993 - 29 June 2022

Abstract Chemotherapy plays an important role in controlling cancer progression, but the long-term use of chemotherapeutic agents can lead to drug resistance and eventually treatment failure. Therefore, elucidation of the mechanism of drug resistance is the key to solve the problem of chemotherapy resistance. In recent years, exosomes derived from tumor cells have received extensive attention from researchers. In this paper, we reviewed the role and mechanism of exosome-mediated tumor drug resistance in recent years, summarized the related studies of exosome and chemotherapy drug resistance, and focused on several different ways by which exosomes participate in More >

ZIQIAN WANG^1,2,#, YAQI LI^1,2,#, DONGYANG WANG^1,2, YINGQIANG SHEN^1,3,4,5,*

BIOCELL, Vol.46, No.7, pp. 1599-1611, 2022, DOI:10.32604/biocell.2022.018530 - 17 March 2022

Abstract Iron-dependent ferroptosis is a form of cell death dependent on iron levels. Cells that undergo ferroptosis have glutathione (GSH) deficiency, reduced Glutathione peroxidase-4 (GPX4) activity and intracellular lipid peroxidation, Mitochondria, lysosomes and many signal pathways are involved in the regulation of ferroptosis. More importantly, many tumor cells resistant to other cell death methods exhibit sensitivity to ferroptosis. Moreover, over recent years, a number of ferroptosis-induced drugs have been recommended for the treatment of malignant tumors. Therefore, the study of ferroptosis is of great significance for future cancer treatments. In this review, we discussed the metabolic More >

Ankur Choksi¹, Shu Wang¹, Michael Phelan¹, Heather Mannuel², Michael Naslund¹, Mohummad Minhaj Siddiqui¹

Canadian Journal of Urology, Vol.28, No.1, pp. 10547-10555, 2021

Abstract Introduction: Complete pathologic response (pT0) at time of cystectomy after neoadjuvant chemotherapy (NAC) has been associated with significantly improved clinical outcomes. The goal of this study is to examine whether race is a predictor of pT0 response to NAC at time of cystectomy.
Materials and methods: We analyzed the records of patients diagnosed with a non-metastatic (M0) muscle-invasive (cT2+) urothelial cell bladder cancer in the National Cancer Database (NCDB) who underwent a cystectomy from 2006 to 2014. The cohort was stratified by whether the patient received NAC prior to cystectomy. Univariate and multivariate logistic regression models were… More >

ZAHRA NASRPOUR NAVAEI¹, GHAZALEH KHALILI-TANHA¹, AMIR SADRA ZANGOUEI², MOHAMMAD REZA ABBASZADEGAN³, MEYSAM MOGHBELI^1,3,*

Oncology Research, Vol.29, No.4, pp. 235-250, 2021, DOI:10.32604/or.2022.025323 - 31 August 2022

Abstract Chemotherapy is one of the main therapeutic modalities for cancer patients. Cisplatin (CDDP), as one of the first-line drugs, is of great importance in the chemotherapy of various tumors. However, a significant percentage of cancer patients are resistant to CDDP treatment. Due to the CDDP side effects on normal tissues, the diagnosis of CDDP resistance is required to suggest the most efficient therapeutic strategies for cancer patients. Several molecular mechanisms and signaling pathways are associated with CDDP response. The PI3K/AKT signaling pathway has a pivotal role in the transmission of extracellular signals into the cells… More >

Xiuhua Weng^*1, Shaohong Luo^*1, Shen Lin^*, Lixian Zhong^†, Meiyue Li^*, Rao Xin^*, Pinfang Huang^*, Xiongwei Xu^*

Oncology Research, Vol.28, No.2, pp. 117-125, 2020, DOI:10.3727/096504019X15707883083132

Abstract To evaluate the cost–utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic nonsmall cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed to compare the lifetime cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE- 042; ClinicalTrials.gov; NCT02220894). Weibull distribution was fitted to simulate the parametric survival functions. Drug costs were collected from official websites, and utility values were obtained from published literature. Total costs, quality-adjusted life years (QALYs), and incremental… More >

Qie Guo^*, Xiao Li^*, Meng-Na Cui^*, Jia-Lin Sun^*, Hong-Yan Ji^*, Bei-Bei Ni^*, Mei-Xing Yan^†

Oncology Research, Vol.28, No.5, pp. 533-540, 2020, DOI:10.3727/096504020X15919605976853

Abstract Cancer is one of the most serious diseases that are harmful to human health. Systemic chemotherapy is an optimal therapeutic strategy for the treatment of cancer, but great difficulty has been encountered in its administration in the form of multidrug resistance (MDR). As an enzyme on the outer cell surface, CD13 is documented to be involved in the MDR development of tumor cells. In this review, we will focus on the role of CD13 in MDR generation based on the current evidence. More >